RxSight
RXST----
Q1 FY2026 EarningsQ2 FY26 preliminary revenue is estimated at $32.0M-$34.0M, including $5.0M-$7.0M from a new Alcon strategic collaboration. Standalone sales reached ~$27M, driven by 24,917 LAL units, despite commercial headwinds from competitive trialing. FY26 guidance for core sales was lowered to $110M-$120M (from $120M-$135M), though full-year revenue remains supported by $30M-$40M in collaboration income. Gross margin guidance improved to 73%-75%.
Financial report interval: 2025.12.31 - 2026.03.31
Preview: RxSight(RXST) predict that the Revenue is 30.89 M (-18.48%), Beat estimate;the EBIT is -17.83 M (-67.03%), Miss estimate;the EPS is -0.38 (-90%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B18.48%
0.03B21.49%
+0.00B3.01%
EBITMiss expectations
-0.02B67.03%
-0.01B35.18%
-0.00B31.85%
EPSMiss expectations
-0.3890.00%
-0.298849.38%
-0.081240.62%
Upcoming earnings report - FY2026 Q2 Earning Release
Available dateAug 5, 2026
Estimate Revenue32.47 M
Estimate EBIT-16.36 M
Estimate EPS-0.3511
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf